Sleep-Focused Talk Therapy Tested in Treatment-Resistant Schizophrenia
Tests a sleep-focused talk therapy against standard talk therapy in people with schizophrenia.
Plain-language title generated from the registry record
Registry title: Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia
Key facts
- Where
- Glostrup, Denmark, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with treatment-resistant schizophrenia or a related non-organic psychosis who also have long-lasting sleep problems. It tests therapy aimed at sleep.
- Age
- 18 to 64 years
- Sex
- All sexes can join
- Disease stage
- Schizophrenia (ICD-10 DF20), chronic paranoid psychosis (DF22), schizo-affective disorder (DF25) or other non-organic psychosis (DF28-DF29). Treatment resistance by TRRIP criteria. Sleep problems for at least 3 months, with an ISI score above 14.
- Earlier treatment
- Stable psychiatric medicine for the last month.
Main reasons for not taking part
- Psychiatric hospital stay in the last six months (more than 1 week, or one that led to big changes in medicine)
- Substance abuse that would get in the way of taking part
- Sleep apnea or CPAP use
- Not legally competent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT06749444, who can take part
Where in Denmark
- Mental Health Centre GlostrupGlostrup, Denmark, DenmarkContact: Jeppe F Johansen, PsychologistTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jimmi Nielsen
- Trial code
- NCT06749444
- Record updated
- 20 January 2026
- Original description
Using a randomized controlled design, the project aims to test if cognitive behavioral therapy interventions specifically targeting sleep disorders can significantly lessen the burden of the disrupted sleep in patients with treatment resistant schizophrenia (TRS) and by proxy lead to a reduction in psychotic symptoms and improvement in quality of life.Read full original descriptionShow less
Cognitive Behavioral Therapy for Sleep and Circadian Disturbances (CBT-I) in Treatment-Resistant Schizophrenia
Using a randomized controlled design, the project aims to test if cognitive behavioral therapy interventions specifically targeting sleep disorders can significantly lessen the burden of the disrupted sleep in patients with treatment resistant schizophrenia (TRS) and by proxy lead to a reduction in psychotic symptoms and improvement in quality of life.
We are including treatment-resistant patients with schizophrenia other nonorganic and chronic psychoses and in addition meeting the criteria of a sleep or circadian disorder. Included patients will be block randomized to either 8-10 sessions of CBT-I (active treatment) with a specific focus on sleep or 8-10 sessions of regularCBT with a specific focus on patients' psychopathology (treatment as usual) approx.1 session/week.
After 12 weeks the full battery of assessments will be repeated forboth groups. Primary analyses will be to identify group-difference in changes using repeated measure ANOVA.
Inclusion: Diagnosed with ICD-10 schizophrenia (DF20), chronic paranoid psychosis (DF22), schizo-affective disorder (DF25) or other non-organic psychosis (DF28-DF29); Treatment resistance according to TRRIP criteria; Sleeping difficulties (minimum duration 3 months); ISI score >14; Stable psychopharmacological treatment the last month; Only legal competent patient can participant.
Exclusion: Psychiatric admission last six months (more than 1 week or resulted in significant changes in psychopharmacological treatment); Substance abuse to a degree that will interfere with participation; Diagnoses of sleep apnea/CPAP use.